Education
About Us
Working with TipRanks
Follow Us
Sensorion SAS (FR:ALSEN)
:ALSEN
ALSEN Stock Chart & Stats
€0.43
€0.00(0.00%)
At close: 4:00 PM EST
€0.43
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.15 - €0.60
Previous CloseN/A
Volume61.80K
Average Volume (3M)540.27K
Market Cap
€188.91M
Enterprise Value€83.15M
Total Cash (Recent Filing)€57.06M
Total Debt (Recent Filing)€1.55M
Price to Earnings (P/E)―
Beta1.16
Next Earnings
Mar 12, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding514,946,960
10 Day Avg. Volume740,129
30 Day Avg. Volume540,266
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)2.50
Price to Sales (P/S)27.15
P/FCF Ratio-8.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€1.50Price Target Upside248.84% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.04
Revenue Forecast (FY)€13.34M
Bulls Say, Bears Say
Bulls Say
Clinical Milestones And Regulatory PathwayPlanned clinical trial application filing for the GJB2 program combined with six-month Audiogene data readouts are positioned by analysts as potential stock catalysts because the program targets a large market and has first-to-market potential.
Financing And Strategic ValidationA strategic equity investment from a major pharmaceutical company provided capital and external validation, extending the company's cash runway and reducing near-term funding uncertainty for planned clinical programs.
Preclinical Efficacy And SafetySENS-601 restored key protein function in animal models of severe prelingual deafness and GLP toxicology in mice and non-human primates reported a favorable safety profile, supporting advancement toward human studies.
Bears Say
Competitive Timing RiskRival gene therapy programs could reach the market first, creating competitive pressure that may reduce the company's potential market share and valuation upside.
Differentiation Requirement Versus CompetitorsIf a competitor secures approval before the company, the investment case would depend on demonstrating clearly superior clinical outcomes, increasing the burden on trial design and efficacy benchmarks.
Early-stage Clinical And Regulatory RiskSENS-601 remains early in development despite encouraging preclinical data, which preserves substantial clinical and regulatory uncertainty that could delay or limit approval prospects.
Sensorion SAS News
ALSEN FAQ
What was Sensorion SAS’s price range in the past 12 months?
Sensorion SAS lowest stock price was €0.15 and its highest was €0.59 in the past 12 months.
What is Sensorion SAS’s market cap?
Sensorion SAS’s market cap is €188.91M.
When is Sensorion SAS’s upcoming earnings report date?
Sensorion SAS’s upcoming earnings report date is Mar 12, 2026 which is in 6 days.
How were Sensorion SAS’s earnings last quarter?
Sensorion SAS released its earnings results on Sep 17, 2025. The company reported -€0.05 earnings per share for the quarter, the consensus estimate of -€0.05 by €0.
Is Sensorion SAS overvalued?
According to Wall Street analysts Sensorion SAS’s price is currently Undervalued.
Does Sensorion SAS pay dividends?
Sensorion SAS does not currently pay dividends.
What is Sensorion SAS’s EPS estimate?
Sensorion SAS’s EPS estimate is -0.06.
How many shares outstanding does Sensorion SAS have?
Sensorion SAS has 514,946,960 shares outstanding.
What happened to Sensorion SAS’s price movement after its last earnings report?
Sensorion SAS reported an EPS of -€0.05 in its last earnings report, expectations of -€0.05. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Sensorion SAS?
Currently, no hedge funds are holding shares in FR:ALSEN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sensorion SAS
Sensorion SA, a clinical-stage biopharmaceutical company, develops drug candidates for the treatment of inner ear disorders in France. The company develops OTOF-GT, a gene therapy development program to restore hearing in people living with Otoferlin deficiency; USHER-T1-GT, a gene therapy development program to for patients suffering from usher syndrome Type 1; and SENS-401, a drug candidate to treat sudden sensorineural hearing loss. Its pipeline also includes various products in development stage for restoring, treating, and preventing inner ear related disorders. The company has a collaboration agreement with Institut Pasteur for gene therapy program for pediatric and adult deafness; and with Sonova Holding AG to introduce genetic analysis for routine diagnosis of progressive hearing loss in adults through a combination of advanced therapeutic interventions and traditional hearing aids. Sensorion SA was founded in 2009 and is headquartered in Montpellier, France.
ALSEN Stock 12 Month Forecast
Average Price Target
€1.50
▲(248.84% Upside)
Technical Analysis
Innate Pharma SA
―
Nanobiotix
―
Transgene
―
OSE Immunotherapeutics SA
―
MaaT Pharma
―
Options Prices
Currently, No data available
---